Resultados globales: 7 registros encontrados en 0.02 segundos.
Artículos, Encontrados 7 registros
Artículos Encontrados 7 registros  
1.
13 p, 3.2 MB Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence / Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Martínez-Barriocanal, Águeda (Vall d'Hebron Institut d'Oncologia) ; Villanueva, Josep (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Cellular senescence is a terminal cell proliferation arrest that can be triggered by oncogenes. One of the traits of oncogene-induced senescence (OIS) is the so-called senescence-associated secretory phenotype or senescence secretome. [...]
2015 - 10.1186/s13058-015-0619-7  
2.
12 p, 5.0 MB Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies / Vicario, Rocio (Vall d'Hebron Institut d'Oncologia) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Zacarias-Fluck, Mariano (Vall d'Hebron Institut d'Oncologia) ; Zhang, Junjie (Vall d'Hebron Institut d'Oncologia) ; Martínez-Barriocanal, Águeda (Vall d'Hebron Institut d'Oncologia) ; Navarro Jiménez, Alexandra (Hospital Universitari Vall d'Hebron) ; Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ; Burgues, Octavio (Hospital Clínic Universitari (València)) ; Lluch, Ana (Hospital Clínic Universitari (València)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Rubio, Isabel T. (Vall d'Hebron Institut d'Oncologia) ; Marangoni, Elisabetta (Institut Curie) ; Deeds, James (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma AG (Suïssa)) ; Schlegel, Robert (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma AG (Suïssa)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Mosher, Rebecca (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ; Boehm, Markus (Novartis Pharma (Suïssa)) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. [...]
2015 - 10.1371/journal.pone.0129876
PloS one, Vol. 10 (june 2015)  
3.
28 p, 6.3 MB PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells / Georgilis, Athena (Imperial College London) ; Klotz, Sabrina (Eberhard Karls University Tübingen) ; Hanley, Christopher J. (University of Southampton) ; Herranz, Nicolas (Imperial College London) ; Weirich, Benedikt (German Cancer Research Centre (DKFZ)) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Leote, Ana Carolina (Universidade de Lisboa) ; D'Artista, Luana (Eberhard Karls University Tübingen) ; Gallage, Suchira (German Cancer Research Centre (DKFZ)) ; Seehawer, Marco (Eberhard Karls University Tübingen) ; Carroll, Thomas (Imperial College London) ; Dharmalingam, Gopuraja (Imperial College London) ; Wee, Keng Boon (Bioinformatics Institute) ; Mellone, Marco (University of Southampton) ; Pombo, Joaquim (Imperial College London) ; Heide, Danijela (German Cancer Research Centre (DKFZ)) ; Guccione, Ernesto (Institute of Molecular and Cell Biology (Singapore)) ; Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Barbosa-Morais, Nuno L. (Universidade de Lisboa) ; Heikenwalder, Mathias (German Cancer Research Centre (DKFZ)) ; Thomas, Gareth J. (University of Southampton) ; Zender, Lars (German Cancer Research Center (DKFZ)) ; Gil, Jesús (Imperial College London)
Oncogene-induced senescence is a potent tumor-suppressive response. Paradoxically, senescence also induces an inflammatory secretome that promotes carcinogenesis and age-related pathologies. Consequently, the senescence-associated secretory phenotype (SASP) is a potential therapeutic target. [...]
2018 - 10.1016/j.ccell.2018.06.007
Cancer Cell, Vol. 34 (july 2018) , p. 85-102.e9  
4.
14 p, 3.0 MB The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1 / Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ; Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ; Luque, Antonio (Vall d'Hebron Institut d'Oncologia) ; Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ; Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Dijcks, Fred A. (Preclinical R&D, The Netherlands) ; Dokter, Wim H.A. (Preclinical R&D, The Netherlands) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Saura, Cristina (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. [...]
2020 - 10.3390/cancers12030670
Cancers, Vol. 12 (march 2020)  
5.
16 p, 5.4 MB HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 / Gorbatenko, A. (Section for Cell Biology and Physiology. Department of Biology. Faculty of Science. University of Copenhagen) ; Søkilde, R. (Department of Clinical Sciences Lund. Oncology and Pathology. Faculty of Medicine. Lund University) ; Sorensen, E.E. (Section for Cell Biology and Physiology. Department of Biology. Faculty of Science. University of Copenhagen) ; Newie, I. (Department of Clinical Sciences Lund. Oncology and Pathology. Faculty of Medicine. Lund University) ; Persson, H. (Department of Clinical Sciences Lund. Oncology and Pathology. Faculty of Medicine. Lund University) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Litman, T. (Department of International Health. Immunology and Microbiology. University of Copenhagen) ; Rovira, Carlos (Department of Clinical Sciences Lund. Oncology and Pathology. Faculty of Medicine. Lund University) ; Pedersen, S.F. (Section for Cell Biology and Physiology. Department of Biology. Faculty of Science. University of Copenhagen)
The HER2 oncogene and its truncated form p95HER2 play central roles in breast cancer. Here, we show that although HER2 and p95HER2 generally elicit qualitatively similar changes in miRNA profile in MCF-7 breast cancer cells, a subset of changes are distinct and p95HER2 shifts the miRNA profile towards the basal breast cancer subtype. [...]
2019 - 10.1038/s41598-019-39733-x
Scientific reports (Nature Publishing Group), Vol. 9 Núm. 1 (january 2019) , p. 3352  
6.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, S. (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y.H. (Experimental Therapeutics Group) ; Gris-Oliver, Albert. (Experimental Therapeutics Group) ; Bonache, S. (Oncogenetics Group) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Bruna, Alejandra (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U.M. (Cancer Research UK. Cambridge Institute) ; Jones, G.N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute (NKI) (Netherlands)) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzman, M. (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, J. (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratù, Ginevra (Cancer Genomics Group) ; Mancuso, F. (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W.J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ; Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J.C. (AstraZeneca (USA)) ; Caldas, C. (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ; Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Jonkers, J. (Cancer Genomics Group) ; Diez, Orland (Hospital Universitari Vall d'Hebron) ; O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  
7.
10 p, 3.3 MB Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts / Morancho, Beatriz (Hospital Universitari Vall d'Hebron) ; Zacarías-Fluck, Mariano ; Esgueva, Antonio (Hospital Universitari Vall d'Hebron) ; Bernadó Morales, Cristina (Hospital Universitari Vall d'Hebron) ; Cosimo, Serena Di (Division of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy) ; Prat, Aleix (Hospital Universitari Vall d'Hebron) ; Cortés, Javier (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Rubio, Isabel T. (Hospital Universitari Vall d'Hebron)
The pleiotropic cytokine IL-6 accelerates the progression of breast cancer in a variety of preclinical models through the activation of the STAT3 (signal transducer and activator of transcription 3) signaling pathway. [...]
2016 - 10.18632/oncotarget.11815
Oncotarget, Vol. 7 (september 2016) , p. 67956-67965  

Vea también: autores con nombres similares
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.